A buyer asks which licence covers the product, and your representative answers in the meeting. The Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945, administered by the Central Drugs Standard Control Organisation, stop being a wall of text. Your team knows the importer holds the import licence in Form 10, that a registration certificate in Form 41 sits behind it, and asks for both early.
Schedule M of the Drugs Rules, 1945 sets the Indian Good Manufacturing Practice requirements, and the buyer holds your Korean certificate up against it. Now your representative says how the two line up and brings batch data for the Active Pharmaceutical Ingredient. The audit conversation stays on the contract, and nobody phones Seoul from the meeting room.
Before the quotation leaves, your team has settled the payment terms and the currency clause. After the order, the customs broker receives the commercial invoice, the packing list, the transport document and, where the Korea-India Comprehensive Economic Partnership Agreement applies, the certificate of origin. Nothing is chased by email while a container waits at the port.
A remark about timelines no longer costs a deal, because your people can read what a polite yes means. Afterwards, when the buyer questions stability or asks who supports the product, the answer is ready: data suited to Indian climate conditions, a named support contact, and a clear rule for telling the importer about product changes.